Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: Neurocrine Biosciences, Inc. discovers, develops, and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company?s products in clinical development stage include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for tourette syndrome schizophrenia; gonadotropin-releasing hormone (GnRH) antagonists for men?s and women?s health, and oncology; antiepileptic drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled receptors for other con
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-11.83%||ROE||-12.96%||ROI|
|Current Ratio||22.19||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.04|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||275.28 M||Cash From Investing Activities||-170.01 M||Cash From Operating Activities||-4.22 M||Gross Profit|
|Net Profit||-23.99 M||Operating Profit||-25.32 M||Total Assets||511.2 M||Total Current Assets||389.42 M|
|Total Current Liabilities||17.55 M||Total Debt||560 K||Total Liabilities||44.27 M||Total Revenue|
|High 52 week||125.85||Low 52 week||68.32||Last close||80.95||Last change||2.59%|
|RSI||33.79||Average true range||3.03||Beta||1.39||Volume||828.99 K|
|Simple moving average 20 days||-3.81%||Simple moving average 50 days||0.07%||Simple moving average 200 days||-18.61%|
|Performance Week||-4%||Performance Month||-9.04%||Performance Quart||-8.52%||Performance Half||-30.58%|
|Performance Year||-5.23%||Performance Year-to-date||13.36%||Volatility daily||2.34%||Volatility weekly||5.23%|
|Volatility monthly||10.72%||Volatility yearly||37.14%||Relative Volume||252.57%||Average Volume||1.21 M|
|New High||New Low|
2019-03-23 10:02:00 | 2 Biotech Takeout Targets Perfect for Biogen
2019-03-20 10:43:28 | Sage Stock Pops on FDA Approval for Postpartum Depression Drug
2019-03-15 09:30:01 | CTLT or NBIX: Which Is the Better Value Stock Right Now?
2019-03-07 09:15:02 | Stocks Slide for Third Straight Day
2019-03-05 16:01:00 | Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2019-03-05 08:01:53 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2019-03-01 12:33:17 | Why These 2 Biotech Stocks Might Be Next On The Takeover List
2019-02-28 11:56:07 | Why Neurocrine Biosciences, Inc. NASDAQ:NBIX Is An Attractive Investment To Consider
2019-02-22 11:31:07 | Voyager Therapeutics stock jumps on 2nd Parkinson's deal
2019-02-12 09:30:02 | CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?
2019-02-08 08:05:10 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2019-02-06 21:20:54 | Edited Transcript of NBIX earnings conference call or presentation 5-Feb-19 9:30pm GMT
2019-02-05 20:04:56 | Neurocrine Biosciences Inc NBIX Q4 2018 Earnings Conference Call Transcript
2019-02-05 18:35:11 | Neurocrine Biosciences NBIX Beats Q4 Earnings Estimates
2019-02-05 17:37:35 | Neurocrine: 4Q Earnings Snapshot
2019-02-05 16:01:00 | Neurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results
2019-02-05 14:30:00 | Neurocrine Biosciences, Inc. to Host Earnings Call
2019-01-31 14:45:22 | Here are Boston-area biotechs pursuing Parkinson's treatments
2019-01-29 13:42:25 | Here's Why Voyager Therapeutics Stock Soared as Much as 62.9% Today
2019-01-29 12:36:57 | Why Is Voyager Therapeutics Soaring Today?
2019-01-29 08:02:24 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2019-01-28 09:33:02 | Will Neurocrine Biosciences Continue to Surge Higher?
2019-01-25 07:45:00 | Analysis: Positioning to Benefit within Neurocrine Biosciences, CONMED, TripAdvisor, Ryder System, Nordstrom, and Express — Research Highlights Growth, Revenue, and Consolidated Results
2019-01-16 16:01:00 | New INGREZZA® valbenazine Analysis Published in the Journal of Affective Disorders Demonstrates Sustained Improvement in Tardive Dyskinesia Symptoms in Patients with Primary Mood Disorders
2019-01-16 06:57:11 | 4 Defensive Stocks to Buy Amid Shutdown and Brexit
2019-01-15 16:48:00 | Here’s your guide to the upcoming biotechnology takeover wave
2019-01-14 08:00:00 | Today's Research Reports on Trending Tickers: Moderna and Neurocrine Biosciences
2019-01-11 16:25:40 | Biotech Stocks Are Enjoying Their Best-Ever Start to the Year
2019-01-11 13:32:26 | Is Neurocrine Biosciences, Inc.’s NASDAQ:NBIX CEO Overpaid Relative To Its Peers?
2019-01-10 12:07:29 | 5 Biotech Stocks That Could Face M&A Next!
2019-01-09 08:05:22 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2019-01-08 08:15:37 | Why Neurocrine Biosciences Stock Rose 9.6% Yesterday
2019-01-07 12:42:05 | Neurocrine Gives Ingrezza Sales View, Updates on Pipeline
2019-01-07 07:15:46 | Neurocrine Biosciences Is a Pharma Stock to Watch
2019-01-07 06:50:00 | Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Loxo Oncology
2019-01-06 10:56:42 | Neurocrine Biosciences Looks Oversold
2019-01-02 16:01:00 | Neurocrine Biosciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
2018-12-31 07:51:00 | 4 of the Fastest Growing Biotech Stocks in 2019
2018-12-14 08:37:01 | Do Options Traders Know Something About Neurocrine Biosciences NBIX Stock We Don't?
2018-12-12 16:35:00 | Why Under Armour, Neurocrine Biosciences, and XPO Logistics Slumped Today
2018-12-12 12:49:00 | Why Neurocrine Biosciences Is Tanking